NCT07924072CompletedPhase 4
Macular Vascular Density After Aflibercept or Ranibizumab Treatment for Diabetic Macular Edema
Macular Vascular Density After Intravitreal Aflibercept Versus Ranibizumab for Treatment of Diabetic Macular Edema
Source: ClinicalTrials.gov · Last updated 9 Nov 2026
Brief summary (registry, in English)
Diabetic macular edema (DME) is a complication of diabetes that causes fluid accumulation in the central retina, potentially leading to impaired vision. Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) medications, including ranibizumab and aflibercept, are commonly used to treat this condition. This prospective, randomized, comparative study aimed to evaluate and compare the effects of intravitreal ranibizumab and aflibercept on macular vascular density in patients with diabetic macular edema using optical coherence tomography angiography (OCTA), a noninvasive imaging technique that visualizes retinal blood vessels. The study included 80 eyes with diabetic macular edema, randomly assigned to two equal treatment groups. One group received ranibizumab, while the other received aflibercept. Each eye received three intravitreal injections. Changes in retinal vascular density, central retinal thickness, and visual acuity were assessed at baseline, 3 months, and 6 months. The study aimed to determine whether OCTA measurements could help evaluate treatment response and identify vascular changes associated with improvement in diabetic macular edema.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 3 Nov 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Benha University
- Diseases
- Diabetic eye disease
- NCT number
- NCT07924072
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 80
- From 1 Jan 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous ocular surgical intervention.
- History of previous intravitreal injections.
Other
- Patients with other ocular pathologies.
- Evidence of vitreomacular traction (VMT) or macular ischemia.
- High myopia (≥6 diopters).
- Presence of corneal opacities.
- Presence of cataract.
- Patients who missed scheduled follow-up visits.
Who the study is looking for
- Patients diagnosed with diabetes mellitus.
- Patients of either sex.
- Patients with no history of previous retinal laser treatment.
- Patients who have not previously received intravitreal injections.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Benha University Hospital | Banhā | Egypt | Unknown status |
The registry text, word for word
This page is information, not medical advice. Discuss any trial with your doctor.